FY2025 EPS Estimates for AnaptysBio Increased by Analyst

AnaptysBio, Inc. (NASDAQ:ANAB) – Analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for AnaptysBio in a report released on Tuesday, November 11th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will earn ($3.15) per share for the year, up from their prior forecast of ($3.56). HC Wainwright has a “Buy” rating and a $52.00 price target on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. HC Wainwright also issued estimates for AnaptysBio’s Q4 2025 earnings at ($1.00) EPS, Q2 2026 earnings at ($0.40) EPS, FY2026 earnings at ($3.92) EPS, FY2027 earnings at ($7.64) EPS, FY2028 earnings at ($3.39) EPS and FY2029 earnings at ($1.13) EPS.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, topping the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The company had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million.

A number of other research firms also recently issued reports on ANAB. Wells Fargo & Company lifted their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Guggenheim lifted their price objective on AnaptysBio from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. Wall Street Zen upgraded AnaptysBio from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, UBS Group reaffirmed a “neutral” rating and set a $20.00 price target (up previously from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, AnaptysBio currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.40.

AnaptysBio Trading Up 1.7%

ANAB stock opened at $33.82 on Thursday. The company’s 50-day moving average price is $30.04 and its 200 day moving average price is $25.12. AnaptysBio has a 52 week low of $12.21 and a 52 week high of $40.96. The company has a market cap of $936.48 million, a P/E ratio of -11.99 and a beta of 0.16.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ANAB. US Bancorp DE lifted its position in AnaptysBio by 126.5% during the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock worth $33,000 after buying an additional 979 shares during the period. Bessemer Group Inc. increased its stake in shares of AnaptysBio by 950.0% during the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 1,377 shares during the period. Osaic Holdings Inc. boosted its position in shares of AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 2,326 shares during the last quarter. Finally, Brooklyn Investment Group grew its holdings in AnaptysBio by 1,779.9% in the first quarter. Brooklyn Investment Group now owns 6,373 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 6,034 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.